| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061657A1 5-ht3 receptor antagonists and methods of use |
| 07/31/2003 | WO2003061656A1 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/31/2003 | WO2003061654A1 Pramipexole for the treatment of hiv dementia |
| 07/31/2003 | WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061642A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias |
| 07/31/2003 | WO2003061638A2 Use of phosphodiesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061637A1 Compositions for pulmonary administration |
| 07/31/2003 | WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061594A2 Methods and compositions for reducing the development of drug tolerance and/or physical dependence |
| 07/31/2003 | WO2003061593A2 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
| 07/31/2003 | WO2003061584A2 Novel substituted benzimidazole dosage forms and method of using same |
| 07/31/2003 | WO2003061580A2 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | WO2003061579A2 Phthalocyanine and porphyrazine pharmaceutical compositions |
| 07/31/2003 | WO2003061577A2 Polyalkylene glycol with moiety for conjugating biologically active compound |
| 07/31/2003 | WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
| 07/31/2003 | WO2003061566A2 Anti-cancer combination and use thereof |
| 07/31/2003 | WO2003061402A2 Reduction of renal damage in companion animals |
| 07/31/2003 | WO2003061365A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 07/31/2003 | WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | WO2003037253A3 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616 |
| 07/31/2003 | WO2003028696A3 Compositions for delivery of drug combinations |
| 07/31/2003 | WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| 07/31/2003 | WO2003018545B1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3? |
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003008630A3 Methods of profiling gene expression, protein or metabolite levels |
| 07/31/2003 | WO2003008578A3 Reagents and methods for identifying gene targets for treating cancer |
| 07/31/2003 | WO2003007995A3 Pharmaceutical preparations containing ion exchange resins charged with fluoroquinolone |
| 07/31/2003 | WO2003006495A3 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 07/31/2003 | WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 07/31/2003 | WO2003000024A3 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 07/31/2003 | WO2003000023A3 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels |
| 07/31/2003 | WO2002099042A3 Cads as modifiers of the p53 pathway and methods of use |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002051410A3 Phenylthiazole and thiazoline derivatives and their use as antiparasitics |
| 07/31/2003 | WO2002036203A3 Azole containing compositions with enhanced antifungal activity |
| 07/31/2003 | WO2002030514A3 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors |
| 07/31/2003 | WO2002020500A3 Materials and methods to potentiate cancer treatment |
| 07/31/2003 | WO2002018444A3 Erbb4 antagonists |
| 07/31/2003 | WO2002015895A3 Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| 07/31/2003 | WO2002012286A3 Stress proteins and peptides and methods of use thereof |
| 07/31/2003 | WO2002004003A3 Composition for the treatment of osteoarthritis |
| 07/31/2003 | WO2001085912A3 Presenilin enhancers |
| 07/31/2003 | US20030144517 Chiral fluoroquinolone arginine salt forms |
| 07/31/2003 | US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases |
| 07/31/2003 | US20030144343 To treat and/or prevent hypertension, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, and endothelial dysfunction or endothelial damage as a consequence of atherosclerotic processes or diabetes |
| 07/31/2003 | US20030144340 By inhibiting fetal cardiac gene expression and interfering with sarcomeric organization |
| 07/31/2003 | US20030144337 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/31/2003 | US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals |
| 07/31/2003 | US20030144331 p53 inhibitors and therapeutic use of the same |
| 07/31/2003 | US20030144330 Peroxidase proliferator activated receptor (PPAR) gamma agonists for playing key role in inducing growth arrest by terminal differentiation of actively proliferating PPAR gamma-expressing cells, particularly transformed adipose cells |
| 07/31/2003 | US20030144323 Phenylalkynes |
| 07/31/2003 | US20030144312 Coadministering a dose of anti-tumor agent and an opioid inhibitor of ATP-binding cassette (ABC) drug transporter protein to increase the concentration of the antitumor agent in the cancer cell; potentiation; crosses blood-brain barrier |
| 07/31/2003 | US20030144311 Propanoic acid derivatives as intergrin receptor antagonists |
| 07/31/2003 | US20030144309 Inhibitors of Src and other protein kinases |
| 07/31/2003 | US20030144306 A liquid oral composition comprising a proton pump inhibitor, e,g, omeprazole, lansoprazole,and a buffer; can also contain a parietal cell activator; acid resistance; side effect reduction; kits; drug delivery; Zollinger-Ellison syndrome |
| 07/31/2003 | US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents |
| 07/31/2003 | US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
| 07/31/2003 | US20030144298 Therapeutic combinations of antihypertensive and antiangiogenics agents |
| 07/31/2003 | US20030144295 A synergistic antiischemic mixture of a tissue plasminogen activator, e.g. alteplase, pamiteplase, and zonampanel(7-imidazol-1-yl-6-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -1-yl acetic acid for strokes or cerebral infarctions |
| 07/31/2003 | US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis |
| 07/31/2003 | US20030144272 Heterocyclic amines such as 2-(2-(N-Methylsulfamoyl)-4-methoxy -phenyl)-N-methyl-N-((1S)-1-phenyl-2-((1-pyrrolidinyl)ethyl)) acetamide, administered as analgesics |
| 07/31/2003 | US20030144271 Methods for the treatment of substance abuse |
| 07/31/2003 | US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents |
| 07/31/2003 | US20030144269 Administering an effective amount of vasopeptidase inhibitor such as omapatrilat or gemopatrilat for reducing hypertension |
| 07/31/2003 | US20030144261 A cyclic peptide useful for treating eating disorder and diabetes |
| 07/31/2003 | US20030144255 Compositions for prevention and treatment of dementia |
| 07/31/2003 | US20030144253 Useful for treating or preventing neuronal damage associated with neurological diseases |
| 07/31/2003 | US20030144252 Bicalutamide and N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4 -amine used as inhibitor of prostate cancer |
| 07/31/2003 | US20030144239 Expression system |
| 07/31/2003 | US20030144234 Administering a cathepsin modulator or enzyme inhibitor, select from a mRNA or a protein; gene expression inhibition, analgesics |
| 07/31/2003 | US20030144232 Expression system |
| 07/31/2003 | US20030144220 Use of CYP2D6 inhibitors in combination therapies |
| 07/31/2003 | US20030144219 Formulations and methods for treatment or amelioration of inflammatory conditions |
| 07/31/2003 | US20030144215 Methods of treatment and pharmaceutical composition |
| 07/31/2003 | US20030144213 Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| 07/31/2003 | US20030144206 Combined use of a GLP-1 compound and modulator of diabetic late complications |
| 07/31/2003 | US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/31/2003 | US20030144198 Increasing gastrointestinal absorption |
| 07/31/2003 | US20030144194 Cancer treatment and prognosis |
| 07/31/2003 | US20030144188 Androgen regulated nucleic acid molecules and encoded proteins |
| 07/31/2003 | US20030144180 Contains as active ingredient a therapeutically effective amount of agent for either enhancing protein kinase c production and/or activation |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143739 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143692 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 07/31/2003 | US20030143690 Peptides and proteins that effect protein phosphorylation; genetic engineered DNA; useful for therapy and diagnosis |
| 07/31/2003 | US20030143683 Introducing a nucleotide sequence encoding prefered amino acid sequences in into a host cell and culturing the host cell in which the peptides are expressed from the nucleotide sequence; human therapeutics and diagnostic protein |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143656 Drug screening compounds which inhibit rate of phosphorylation by kinase having hydrophobic pocket domain; surface plasmon resonance; fusion proteins; anticancer-/ antidiabetic agents |
| 07/31/2003 | US20030143623 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/31/2003 | US20030143622 Human RNA binding proteins |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143522 Screening and use of agents which block or activate intein splicing utilizing natural or homologous exteins |
| 07/31/2003 | US20030143312 Baking adjuvant |
| 07/31/2003 | US20030143281 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |